Celcuity (CELC) Other Non Operating Income (2020 - 2026)
Celcuity's (CELC) quarterly Other Non Operating Income came in at -$728756.0 in Q4 2024, up 32.92% YoY from -$548262.4 in Q1 2024, and down 371.81% on a QoQ basis from $268110.0 in Q3 2024.
Analysis
Celcuity (CELC) Other Non Operating Income (2020 - 2026) Analysis & Trends
Celcuity (CELC) has 5 years of Other Non Operating Income data on file, last reported at -$728756.0 in Q4 2024.
- Quarterly Other Non Operating Income rose 32.92% year-over-year to -$728756.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $982000.0 (up 102.89% YoY) and the FY2025 annual result came in at $1.4 million, up 38.29% from the prior year.
- Other Non Operating Income fell to -$728756.0 in Q4 2024, from $268110.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $881380.0 in Q1 2024 to a low of -$1.1 million in Q4 2023.
- A 5-year average of -$39164.6 and a median of $443.0 in 2020 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2022 — Other Non Operating Income tumbled 418572.55% — and 2023, when it soared 297.27%.
- Tracing CELC's Other Non Operating Income over 5 years: stood at $443.0 in 2020, then plunged by 97754.18% to -$432608.0 in 2021, then jumped by 113.37% to $57858.0 in 2022, then tumbled by 1977.73% to -$1.1 million in 2023, then soared by 32.92% to -$728756.0 in 2024.
- The last three Other Non Operating Income figures came in at -$728756.0 (Q4 2024), $268110.0 (Q3 2024), and $561266.0 (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Celcuity | 5.23 Bn | 5.23 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -11.48 Mn |
| Dec 31, 2024 | -728,756.00 |
| Sep 30, 2024 | 268,110.00 |
| Jun 30, 2024 | 561,266.00 |
| Mar 31, 2024 | 881,380.00 |
| Dec 31, 2023 | -1.02 Mn |
| Sep 30, 2023 | 493,497.00 |
| Jun 30, 2023 | 467,798.00 |
| Mar 31, 2023 | 609,120.00 |
| Dec 31, 2022 | 2.38 Mn |
| Sep 30, 2022 | -250,166.00 |
| Jun 30, 2022 | -359,799.00 |
| Mar 31, 2022 | -426,842.00 |
| Dec 31, 2021 | -432,608.00 |
| Sep 30, 2021 | -427,460.00 |
| Jun 30, 2021 | -389,384.00 |
| Mar 31, 2021 | 102.00 |
| Dec 31, 2020 | 443.00 |
| Sep 30, 2020 | 5,777.00 |
| Jun 30, 2020 | 11,952.00 |